



Supple Figure 1:


Workflow of QuPath Analysis software to measure the DAB stain intensity



Open QuPath software, open image, select H-DAB and apply




Go to tools, select rectangle icon and using the rectangle icon select the area of the image need to be analysed (borders of the selected area show yellow in color)




Go to analyze, select cell detection and finally positive cell detection.

Supple Fig 1




H-Score obtained as marked by red arrow. In this case the H-score value is 22




Black arrow mark denotes nuclear staining of L1ORF1p and L1ORF2p

Supple Fig 2: Distribution of L1ORF1p and L1ORF2p in the nucleus and cytoplasm in the operated oral cancer samples




Supple Fig 3A: IHC staining with anti-L1ORF1p (Non-recurrent) (n=35)




Supple Fig 3A: IHC staining with anti-L1ORF1p (Non-recurrent) (n=35)


C108




C111




C114



Supple Fig 3A: IHC staining with anti-L1ORF1p (Non-recurrent) (n=35)




Supple Fig 3B: IHC staining with anti-L1ORF1p (Recurrent) (n=35)




Supple Fig 3B: IHC staining with anti-L1ORF1p (Recurrent) (n=35)


C109




C112



C113




Supple Fig 3B: IHC staining with anti-L1ORF1p (Recurrent) (n=35)




Supple Fig 3C: IHC staining with anti-L1ORF2p (Non-recurrent) (n=35)


C36




C45




C75




C89




C40




C52




C80




C91




C41




C63




C84




C95




C43




C70



C88




C104




Supple Fig 3C: IHC staining with anti-L1ORF2p (Non-recurrent) (n=35)


C108




C111



C114




Supple Fig 3C: IHC staining with anti-L1ORF2p (Non-recurrent) (n=35)




Supple Fig 3D: IHC staining with anti-L1ORF2p (Non-recurrent) (n=35)


C62




C73




C92




C98




C69




C83




C93




C100




C71




C86




C94




C102




C72




C90



C97




C103




Supple Fig 3D: IHC staining with anti-L1ORF2p (Non-recurrent) (n=35)


C109




C112




C113




Supple Fig 3D: IHC staining with anti-L1ORF2p (Non-recurrent) (n=35)




Supple Fig 4: L1ORF1p expression in established oral cancer cell line







Supple Fig 5B: IHC staining with anti-P53 (Recurrent) (n=25)




Supple Fig 6A: IHC staining with anti-PCNA (Non-recurrent) (n=25)




Supple Fig 6B: IHC staining with anti-PCNA (Recurrent) (n=25)




Supple Fig 7A: IHC staining with CD105 (Non-recurrent) (n=25)




Supple Fig 7B: IHC staining with CD105 (Recurrent) (n=25)




Supple Fig 8A: IHC staining with anti-Ki67 (Non-recurrent) (n=25)




Supple Fig 8B: IHC staining with anti-Ki67 (Recurrent) (n=25)




Supple Fig 9A: IHC staining with anti-MMP9 (Non-recurrent) (n=25)




Supple Fig 9B: IHC staining with anti-MMP9 (Recurrent) (n=25)




Supple Fig 10A: IHC staining with anti-EGFR (Non-recurrent) (n=25)




Supple Fig 10B: IHC staining with anti-EGFR (Recurrent) (n=25)




Supple Fig 11A: IHC staining with anti-CD44 (Non-recurrent) (n= 25)



Supple Fig 11B: IHC staining with anti-CD44 (Recurrent) (n= 25)



Supple Fig 12A: IHC staining with anti-PDL1 (Non-recurrent) (n=25)



Supple Fig 12B: IHC staining with anti-PDL1 (Recurrent) (n=25)